Is Invokamet in shortage in 2026? Get the latest update on availability, why it's hard to find, what it costs, and how to fill your prescription.
If you've had trouble finding Invokamet at your pharmacy recently, you're probably wondering: is there a shortage? The short answer is that Invokamet is not currently on the FDA's official drug shortage list as of early 2026. But that doesn't mean it's easy to find.
Many patients report difficulty locating Invokamet at their regular pharmacy, and there are real reasons why. This article breaks down the current availability situation, what's driving the problem, what Invokamet costs in 2026, and what you can do to make sure you don't miss a dose.
Invokamet (Canagliflozin/Metformin) is manufactured by Janssen Pharmaceuticals, a Johnson & Johnson company. As of March 2026, the medication remains in active production and is not in a formal shortage.
However, availability varies significantly from pharmacy to pharmacy. Here's why:
So while there's no official shortage, the practical experience for patients can feel like one. For tips on locating it, see our guide on how to find Invokamet in stock near you.
Several factors contribute to the difficulty patients face:
When a medication has generic versions available, multiple manufacturers produce it, creating abundant supply. Invokamet's patent protection (expected through 2029) means Janssen is the sole producer. This limits overall supply compared to widely available generics like Metformin.
Many health insurance plans require prior authorization or step therapy before covering Invokamet. Some plans prefer alternative SGLT2/Metformin combinations like Synjardy or Xigduo XR. When fewer patients are approved for Invokamet through insurance, pharmacies have less incentive to stock it.
While Invokamet itself hasn't experienced major shortages, Metformin — one of its two active ingredients — faced significant supply disruptions in 2020 due to NDMA (a potential carcinogen) contamination recalls. Those recalls affected several generic Metformin manufacturers. Although that issue has been resolved, it's a reminder that supply chain problems can impact diabetes medications at any time.
As more independent pharmacies close and chain pharmacies consolidate, inventory decisions are increasingly made at the corporate level. Corporate pharmacy chains tend to stock high-volume, high-turnover medications and may deprioritize niche brand-name products like Invokamet.
Here's what you can expect to pay for a 30-day supply (60 tablets) of Invokamet in 2026:
For a complete breakdown of savings options, read our guide on how to save money on Invokamet.
While waiting for a generic Invokamet, here are some developments that may help patients:
Here are your best strategies:
Invokamet isn't in an official shortage in 2026, but real-world availability challenges can make it feel that way. The combination of being a brand-only product, insurance restrictions, and pharmacy stocking decisions means you may need to be proactive about filling your prescription.
The most important thing is to never skip doses of your diabetes medication. If you can't find Invokamet, use Medfinder to locate it, or work with your doctor to find an alternative that keeps your blood sugar under control. Your health comes first.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
